Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy

F Morschhauser; J Radford; A van Hoof; I Kuss; A Chlistalla; A Hagenbeek; C Hugh-Jones

doi:10.1182/blood.V106.11.4795.4795

Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy

F Morschhauser, J Radford, A van Hoof, I Kuss, A Chlistalla, A Hagenbeek, C Hugh-Jones

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	Undefined
Article number	4795
Pages (from-to)	279B-279B
Number of pages	1
Journal	Blood
Volume	106
Issue number	11 Part 2
DOIs	https://doi.org/10.1182/blood.V106.11.4795.4795
Publication status	Published - 16 Nov 2005

Access to Document

10.1182/blood.V106.11.4795.4795

Cite this

Morschhauser, F., Radford, J., van Hoof, A., Kuss, I., Chlistalla, A., Hagenbeek, A., & Hugh-Jones, C. (2005). Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy. Blood, 106(11 Part 2), 279B-279B. Article 4795. https://doi.org/10.1182/blood.V106.11.4795.4795

@article{a0f6a35ea53b496c8cb2f149f5633635,

title = "Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy",

author = "F Morschhauser and J Radford and {van Hoof}, A and I Kuss and A Chlistalla and A Hagenbeek and C Hugh-Jones",

year = "2005",

month = nov,

day = "16",

doi = "10.1182/blood.V106.11.4795.4795",

language = "Undefined",

volume = "106",

pages = "279B--279B",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "11 Part 2",

}

Morschhauser, F, Radford, J, van Hoof, A, Kuss, I, Chlistalla, A, Hagenbeek, A & Hugh-Jones, C 2005, 'Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy', Blood, vol. 106, no. 11 Part 2, 4795, pp. 279B-279B. https://doi.org/10.1182/blood.V106.11.4795.4795

Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy. / Morschhauser, F; Radford, J; van Hoof, A et al.
In: Blood, Vol. 106, No. 11 Part 2, 4795, 16.11.2005, p. 279B-279B.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy

AU - Morschhauser, F

AU - Radford, J

AU - van Hoof, A

AU - Kuss, I

AU - Chlistalla, A

AU - Hagenbeek, A

AU - Hugh-Jones, C

PY - 2005/11/16

Y1 - 2005/11/16

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000233426101497&KeyUID=WOS:000233426101497

U2 - 10.1182/blood.V106.11.4795.4795

DO - 10.1182/blood.V106.11.4795.4795

M3 - Meeting Abstract

SN - 0006-4971

VL - 106

SP - 279B-279B

JO - Blood

JF - Blood

IS - 11 Part 2

M1 - 4795

ER -

Morschhauser F, Radford J, van Hoof A, Kuss I, Chlistalla A, Hagenbeek A et al. Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy. Blood. 2005 Nov 16;106(11 Part 2):279B-279B. 4795. doi: 10.1182/blood.V106.11.4795.4795

Assessing the predictive value of plasma FLT3-L levels for hematologic toxicity after yttrium-90 ibritumomab tiuxetan ([Y-90]-Zevalin) given as consolidation in patients with advanced B-cell follicular NHL responding to first line therapy

Access to Document

Other files and links

Cite this